Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

Immunotherapy using PD-1 and CTLA4 inhibitors to stimulate T cell immunity has achieved significant clinical success. However, only a portion of patients benefit from T cell-based immunotherapy. Macrophages, the most abundant type of innate immune cells in the body, play an important role in elimina...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Tailong, Li, Baiyong, Wang, Yifei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009010/
https://www.ncbi.nlm.nih.gov/pubmed/35418166
http://dx.doi.org/10.1186/s40364-022-00373-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009010/
https://www.ncbi.nlm.nih.gov/pubmed/35418166
http://dx.doi.org/10.1186/s40364-022-00373-5

Ejemplares similares